跳至主要内容
临床试验/NCT03059511
NCT03059511终止1 期

Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants: A Single Center, Open-label, Prospective Study

University Children's Hospital, Zurich1 个研究点 分布在 1 个国家目标入组 51 人开始时间: 2017年3月3日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
终止
发起方
入组人数
51
试验地点
1
主要终点
Pharmacokinetics (Bioavailability of Nalbuphine intranasal)

研究概览

简要总结

To assess pharmacokinetics parameters for nalbuphine after intravenous and intranasal administration in infants. Also effect on pain score: Neonatal Infant Pain Score (NIPS) and safety will be evaluated with summary of Adverse Events.

Inclusion criteria are: Infants 29 days-3 months, minimum Body weight 3.0 kg, Indications: septical work up.

Exclusion criteria are: Infants who were born prematurely (before 37 weeks gestation), known kidney or liver disease, known chronic illness.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
29 Days 至 3 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Infants 29 days-3 months
  • Minimum Body weight 3.0 kg
  • Indications: septical work up
  • Parent has been informed about the study and has signed Informed Consent Form

排除标准

  • Infants who were born prematurely (before 37 weeks gestation)
  • Known kidney or liver disease
  • Known chronic illness
  • Documented previous adverse reaction to nalbuphine
  • Treatment with a depressant drug within 5 days prior to study
  • Epistaxis, nose trauma (only for the intranasal application)
  • Barriere of language

研究组 & 干预措施

intravenous

Active Comparator

single iv application of nalbuphine 0.05mg/kg

干预措施: Nalbuphine (Drug)

intranasal

Active Comparator

single intranasal application of nalbuphine 0.1mg/kg in infants.

干预措施: Nalbuphine (Drug)

结局指标

主要结局

Pharmacokinetics (Bioavailability of Nalbuphine intranasal)

时间窗: One Visit = approximately 6 hours

Bioavailability of Nalbuphine intranasal

Pharmacokinetics (Area under the plasma concentration-time)

时间窗: One Visit = approximately 6 hours

Area under the plasma concentration-time from the first to the last sample

Pharmacokinetics (Maximum Plasma concentration)

时间窗: One Visit = approximately 6 hours

Maximum Plasma concentration

Pharmacokinetics (Half-life time)

时间窗: One Visit = approximately 6 hours

Half-life time

Pharmacokinetics (Time to reach Maximum Plasma concentration)

时间窗: One Visit = approximately 6 hours

Time to reach Maximum Plasma concentration

次要结局

  • Effect on pain (Neonatal Infant Pain Score)(One Visit = approximately 6 hours)
  • Adverse Events(One Visit = approximately 6 hours)

研究者

发起方
University Children's Hospital, Zurich
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验